Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in ...

Khaberni - A medical study has revealed promising results in treating moderate to severe psoriasis, one of the most ...

AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor, risankizumab ...

Long-term follow-up of Taiwanese children with chronic hepatitis B virus (HBV) infection showed that 3.29% had HBV surface antigen (HBsAg) seroconversion after antiviral treatment while another 3.86% ...

The TNF alpha inhibitors adalimumab and infliximab were associated with an increased risk for serious infection in patients with plaque psoriasis.

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) – UC and ...

AbbVie to present data from multiple studies of Rinvoq, Humira & Skyrizi at the 2019 ACR/ARP) meeting: North Chicago, Illionis Tuesday, November 5, 2019, 16:00 Hrs [IST] AbbVie, a ...